This is a working overview of Thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-16. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
== External links == Media related to Copper(II) sulfate at Wikimedia Commons International Chemical Safety Card 0751 International Chemical Safety Card 1416 National Pollutant Inventory – Copper and compounds fact sheet
Nucleic acid was, partially, first discovered by Friedrich Miescher in 1869 at the University of Tübingen, Germany. He discovered a new substance, which he called nuclein and which - depending on how his results are interpreted in detail - can be seen in modern terms either as a nucleic acid-histone complex or as the actual nucleic acid. Phoebus Levene determined the basic structure of nucleic acids. In the early 1880s, Albrecht Kossel further purified the nucleid acid substance and discovered its highly acidic properties. He later also identified the nucleobases. In 1889 Richard Altmann created the term nucleic acid – at that time DNA and RNA were not differentiated. In 1938 Astbury and Bell published the first X-ray diffraction pattern of DNA. In 1944 the Avery–MacLeod–McCarty experiment showed that DNA is the carrier of genetic information and in 1953 Watson and Crick proposed the double-helix structure of DNA. Experimental studies of nucleic acids constitute a major part of modern biological and medical research, and form a foundation for genome and forensic science, and the biotechnology and pharmaceutical industries.
=== Produce === Preservation and processing of fresh produce poses many biological engineering challenges. Understanding of biology is particularly important to processing produce because most fruits and vegetables are living organisms from the time of harvest to the time of consumption. Before harvesting, understanding of plant ontogeny, or origin and development, and the manipulation of these developmental processes are key components of the industrial agriculture process. Understanding of plant developmental cycles governs how and when plants are harvested, impacts storage environments, and contributes to creating intervention processes. Even after harvesting, fruits and vegetables undergo the biological processes of respiration, transpiration, and ripening. Control over these natural plant processes should be achieved to prevent food spoilage, sprouting or growth of produce during storage, and reduction in quality or desirability, such as through wilting or loss of desirable texture.
Sources: en.wikipedia.org
== Early life and education == Cameron was born in Champaign, Illinois. The oldest of three brothers, he grew up in the Chicago suburb, Westchester, and graduated in 1975 from Proviso West High School, Hillside, Illinois. Cameron graduated from Duke University (1979) with a B.S.E. in Biomedical Engineering. In May 1979 he joined Advanced Harvesting Systems, a start-up company focused on large-scale plant protein purification, as the first non-founding member of the company. He was married in August 1979 to Sally Jo Clark. Cameron started graduate school at the Massachusetts Institute of Technology in July 1981 and graduated with a Ph.D. in biochemical engineering in December 1986. His Ph.D. advisor was Charles L. Cooney. His Ph.D. thesis was titled “The Production of R-1,2-Propanediol by Clostridium thermosaccharolyticum.”
District Court judicial nominees who Kennedy believed were not qualified: Jeff Mateer, Brett Talley, and Matthew S. Petersen. The White House withdrew all three nominations. On December 13, 2017, during Petersen's confirmation hearing before the Senate Judiciary Committee, Kennedy asked Petersen about basic legal procedure, whether he knew what the Daubert standard was and what a motion in limine was. Petersen struggled to answer. Kennedy also voted against the nomination of Gregory G. Katsas to the D.C. Circuit, but Katsas was confirmed. On April 7, 2017, Kennedy voted to confirm Neil Gorsuch to the United States Supreme Court. Kennedy participated in Gorsuch's confirmation as a member of the Judiciary Committee. During the confirmation process, Kennedy said, “Neil Gorsuch is obviously very well-qualified based on his education and background, but I want to know what’s in his heart. I want to know what he thinks about past Supreme Court decisions and how the justices reached those decisions. I want to know whether he thinks personal preferences have a role in the judicial decision-making. I want to know if he knows the name of the person who cleans his office. Also, I'm rather fond of the U.S. Constitution, and I want to make sure he is, too." On October 6, 2018, Kennedy voted to confirm Brett Kavanaugh to the Supreme Court. As a member of the Judiciary Committee, Kennedy participated in Kavanaugh's contentious nomination hearing after Christine Blasey Ford accused Kavanaugh of sexual assault.
These initially involved groups of soldiers that were inserted by helicopter, and were later expanded with paratroopers. The Rhodesian Light Infantry often provided the soldiers for fireforce teams. A key element of the Selous Scouts' methods was 'turning' captured insurgents to join the Rhodesian security forces. This was normally attempted shortly after insurgents were captured, with them being both threatened and offered incentives. The captured insurgent was usually approached by a former insurgent. In the resulting conversation, the former insurgent emphasised the hardships insurgents were experiencing and that those who were captured faced the death penalty under the Law and Order (Maintenance) Act. This legislation imposed severe penalties for people found to be members of subversive organisations, including the death penalty or long prison terms. The captured insurgent was also offered a lump sum payment as well as a soldier's salary if they agreed to fight for the Rhodesian government. If an insurgent agreed to be 'turned' and passed further vetting, they were assigned to a Selous Scout team and operated in regions in which they would not be recognised. Where possible, their family was housed on a Selous Scouts base. Only a small number of 'turned' insurgents ever deserted or betrayed the unit. Some of the prisoners captured by the Selous Scouts who refused to be 'turned' were killed. One of the tactics used by the Selous Scouts was to violate local customs while posing as insurgents with the goal of reducing support for the actual insurgents.
This phenomenon was used in the design of light meters and similar devices. Selenium's semiconductor properties found numerous other applications in electronics. The development of selenium rectifiers began during the early 1930s, and these replaced copper oxide rectifiers because they were more efficient. These lasted in commercial applications until the 1970s, following which they were replaced with less expensive and even more efficient silicon rectifiers. Selenium came to medical notice later because of its toxicity to industrial workers. Selenium was also recognized as an important veterinary toxin, which is seen in animals that have eaten high-selenium plants. In 1954, the first hints of specific biological functions of selenium were discovered in microorganisms by biochemist, Jane Pinsent. It was discovered to be essential for mammalian life in 1957. In the 1970s, it was shown to be present in two independent sets of enzymes. This was followed by the discovery of selenocysteine in proteins. During the 1980s, selenocysteine was shown to be encoded by the codon UGA. The recoding mechanism was worked out first in bacteria and then in mammals (see SECIS element).
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.